{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:19:01Z","timestamp":1793999941430,"version":"4.8.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CHRU de Brest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Between March to December 2024, we observed a PEG-IFN\u03b12a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFN\u03b12a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (<jats:italic>p<\/jats:italic>=0.04). No hematological or only partial responses were more frequent in the impacted group (<jats:italic>p<\/jats:italic>=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF &lt;10%. Eight patients stopped the drug because of VAF &lt;4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.<\/jats:p>","DOI":"10.1007\/s00277-025-06510-y","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T02:38:09Z","timestamp":1752719889000},"page":"4263-4266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Consequences and impacts of PEG-IFN\u03b12a shortage: first lessons from a MPN French center"],"prefix":"10.1007","volume":"104","author":[{"given":"Laura","family":"Cailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne-Corentin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Richard","family":"Eveillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pan-Petesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Herbreteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanig","family":"Civi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tempescul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalbies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bagacean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"11","key":"6510_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"1","key":"6510_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Ghirardi A, Carobbio A et al (2024) Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J 14(1):188","journal-title":"Blood Cancer J"},{"issue":"6","key":"6510_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770","journal-title":"J Clin Oncol"},{"issue":"19","key":"6510_CR4","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R et al (2023) Ruxolitinib versus best available therapy for polycythemia Vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol 41(19):3534\u20133544","journal-title":"J Clin Oncol"},{"issue":"8","key":"6510_CR5","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S et al (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072","journal-title":"Blood"},{"issue":"3","key":"6510_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3324\/haematol.2017.181297","volume":"103","author":"JC Ianotto","year":"2018","unstructured":"Ianotto JC, Chauveau A, Boyer-Perrard F et al (2018) Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French intergroup of myeloproliferative neoplasms (FIM) study. Haematologica 103(3):438\u2013446","journal-title":"Haematologica"},{"issue":"4","key":"6510_CR7","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301\u2013e311","journal-title":"Lancet Haematol"},{"issue":"3","key":"6510_CR8","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196\u2013e208","journal-title":"Lancet Haematol"},{"issue":"1","key":"6510_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/hematology.2024000577","volume":"2024","author":"JJ Kiladjian","year":"2024","unstructured":"Kiladjian JJ (2024) Pegylated interferon: the who, why, and how. Hematol Am Soc Hematol Educ Program 2024(1):535\u2013540","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Supplement1","key":"6510_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"R De Daltro","year":"2020","unstructured":"De Daltro R, Soret-Dulphy J, Zhao LP et al (2020) Interferon-Alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood 136(Supplement1):35\u201336","journal-title":"Blood"},{"issue":"10","key":"6510_CR11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol 96(10):1653\u20131665","journal-title":"Ann Hematol"},{"issue":"5","key":"6510_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.psym.2018.01.006","volume":"59","author":"DC McFarland","year":"2018","unstructured":"McFarland DC, Shaffer KM, Polizzi H et al (2018) Associations of physical and psychologic symptom burden in patients with Philadelphia Chromosome-Negative myeloproliferative neoplasms. Psychosomatics 59(5):472\u2013480","journal-title":"Psychosomatics"},{"issue":"4","key":"6510_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3324\/haematol.2017.180448","volume":"103","author":"R Le Calloch","year":"2018","unstructured":"Le Calloch R, Lacut K, Le Gall-Ianotto C et al (2018) Non-adherence to treatment with cytoreductive and\/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica 103(4):607\u2013613","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06510-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:58Z","timestamp":1757663338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06510-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6510"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06510-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data presented here are extracted from the OBENE ambispective registry. This study has been running since 2015, after acceptance from the Brest Ethical Committee. OBENE is registered on ClinicalTrial website (NCT02897297). Patients are included after information and non-opposition expression. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"For this publication, there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}